AstraZeneca PLC
AZN: XLON (GBR)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
GBX 31,653.00 | Vwzd | Vzjhrlrm |
AstraZeneca Posts Strong Q3, Buoyed by Broad Portfolio Support As the Pipeline Continues To Advance
AstraZeneca reported strong third-quarter results ahead of our expectations, and we plan to slightly raise our fair value estimate based on the results and solid pipeline advancements. We continue to view the stock as undervalued with the market not fully appreciating the strong growth outlook and the innovative pipeline that also supports the firm’s wide moat.